F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Prise en charge des métastases osseuses
TL;DR: A rational decisional algorithm is proposed for the treatment strategy of secondary locations of bone metastasis, which vary according to the tumor site, the symptomatology (pain, neurologic symptoms), and the presence of complications.
Journal ArticleDOI
Troubles des fonctions supérieures chez un fumeur
J. Rakotomizao,Fabrice Barlesi,G Lima,Christophe Doddoli,Céline Gimenez,A. Palot,Jean-Pierre Kleisbauer +6 more
TL;DR: In this paper, the authors propose a diagnostic of encephalomyelite paraneoplasique (EMP) in the case of cancer bronchique a petites cellules (CPC).
Journal ArticleDOI
P-441 CYFRA 21-1 is a prognostic determinant in non-small cell lung cancer: Results of a meta-analysis in 2063 patients
Jean-Louis Pujol,Olivier Molinier,Werner Ebert,Fabrice Barlesi,Jean-Pierre Daurès,Gianfranco Buccheri,Marianne Paesmans,Elisabeth Quoix,D Moro,Marika Szturmowicz,Jeanne-Marie Bréchot +10 more
Journal ArticleDOI
Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
Yi-Long Wu,Ji-Youn Han,Terufumi Kato,Fabrice Barlesi,Edward B. Garon,Federico Cappuzzo,Yuji Shibata,Nathalie D. Smith,Sadhvi Khanna,Riccardo Belli,A. Yovine,Daniel Sw Tan +11 more
TL;DR: The primary endpoint is the incidence of dose limiting toxicities during the first 21 days of treatment, and investigator-assessed overall response rate (ORR), duration of response (DOR), time to response (TTR), disease control rate (DCR) and progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors version 1.1.
Journal ArticleDOI
385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Fabrice Barlesi,Juergen Wolf,Myung-Ju Ahn,Robert C. Doebele,Luis Paz-Ares,Christian D. Rolfo,Salvatore Siena,Takashi Seto,Yuichiro Ohe,S-H.I. Ou,Matthew G Krebs,A. Kapre,E. Piault-Louis,S. McCallum,S. Osborne,A. Aziez,A. Drilon +16 more